What is claimed is:
1. A compound having the structure of the following Formula 1:
12
wherein, R, R, and R are each independently selected from the group consisting of hydrogen and methyl;
Ra to Rd, and R1 to R18 are each independently selected from the group consisting of H, OH, OCOCH3, COOH, CH2OH, or alkyl having 1 to 5 carbon atoms and alkoxy alkyl having 1 to 5 carbon atoms;
m and n each represent an integer selected from the group consisting of 1, 2, 3, 4 and 5;
x, y, and z each represent a mole fraction ranging from about 0.01 to about 0.99.
2. The compound of claim 1 which is poly9-anthracenemethylimineethylacrylate-(2-hydroxyethylacrylate)-(9-anthracenemethylmethacrylate), wherein R and R are hydrogen, R is methyl, Ra to Rd are methyl, R1 to R18 are each independently hydrogen, m and n each represent 2, and x, y and z are each 0.1, 0.5, and 0.4, respectively.
3. The compound of claim 1 which is poly9-anthracenemethylimineethylmethacrylate-(2-hydroxyethylmethacrylate)-(9-anthraceneacrylate), wherein R, and R are each methyl, R is hydrogen, Ra to Rd are methyl, R1 to R18 are each hydrogen, m and n each represent 2, and x, y and z are each 0.1, 0.5, and 0.4, respectively.
4. The compound of claim 1 which is poly9-anthracenemethyliminepropylacrylate-(3-hydroxypropylacrylate)-(9-anthracenemethylmethacrylate), wherein R and R are hydrogen, R is methyl, Ra to Rd are methyl, R1 to R18 are each hydrogen, m and n are each 3, and x, y and z are each 0.1, 0.5, and 0.4, respectively.
5. The compound of claim 1 which is poly9-anthracenemethyliminepropylmethacrylate-(2-hydroxyethylmethacrylate)-(9-anthraceneacrylate), wherein R and R are each methyl, R is hydrogen, Ra to Rd are methyl, R1 to R18 are each hydrogen, m is 3, and x, y and z are each 0.1, 0.5, and 0.4, respectively.
6. The compound of claim 1 which is poly9-anthracenemethyliminepropylmethacrylate-(3-hydroxypropylacrylate)-(9-anthracenemethylmethacrylate), wherein R and R are each independently methyl, R is hydrogen, Ra to Rd are methyl, R1 to R18 are each hydrogen, m and n are each 3, and x, y and z are each 0.1, 0.5, and 0.4, respectively.
7. The compound of claim 1 which is poly9-anthracenemethyliminepropylmethacrylate-(4-hydroxybutylacrylate)-(9-anthracenemethylmethacrylate), wherein R and R are each methyl, R is hydrogen Ra to Rd are methyl, R1 to R18 are each hydrogen, m and n are each 3 and 4, respectively, and x, y and z are each 0.1, 0.5, and 0.4, respectively.
8. A method for preparing a compound of claim 1, which comprises:
reacting 9-anthracenemethyliminealkylacrylate monomer, hydroxyalkyl-acrylate monomer, and 9-anthracenealkylmethacrylate in a solvent to obtain a product; and
polymerizing the product with a polymerization initiator.
9. The method of claim 8, wherein the solvent is selected from the group consisting of tetrahydrofuran, toluene, benzene, methylethylketone, dioxane and mixtures thereof.
10. The method of claim 8, wherein the polymerization initiator is selected from the group consisting of 2,2-azobisisobutyronitrile, acetylperoxide, laurylperoxide, t-butylperoxide, and mixtures thereof.
11. The method of claim 8, wherein the polymerization is carried out at a temperature ranging from about 50 to about 90 C.
12. An anti-reflective coating composition comprising:
a compound of claim 1 and a compound of the following Formula 2:
13
wherein, R19 and R20 are each alkyl having 1 to 10 carbon atoms or alkoxy having 1 to 10 carbon atoms; and
R21 is hydrogen or methyl.
13. The composition of claim 12 further comprising an anthracene derivative additive selected from the group consisting of anthracene, 9-anthracenemethanol, 9-anthracenecarbonitrile, 9-antracene carboxylic acid, ditranol, 1,2,10-anthracentriol, anthraflavonic acid, 9-anthraldehydeoxime, 9-anthraldehyde, 2-amino-7-methyl-5-oxo-5H-1benzopyrano2,3-bpyridine-3-carbonitrile, 1-aminoanthraquinone, anthraquinone-2-carboxylic acid, 1,5-dihydroxyanthraquinone, anthrone, 9-anthryle trifluoromethylketone, 9-alkylanthracene derivatives, 9-carboxylanthracene derivatives, 1-carboxylanthracene derivatives and mixtures thereof.
14. A method for preparing an anti-reflective coating comprising:
dissolving the said compound of claim 1 and the compound of Formula 2 in an organic solvent to obtain a solution;
filtering the solution alone or in combination with an anthracene derivative additive selected from the group consisting of anthracene, 9-anthracenemethanol, 9-anthracenecarbonitrile, 9-antracene carboxylic acid, ditranol, 1,2,10-anthracentriol, anthraflavonic acid, 9-anthraldehydeoxime, 9-anthraldehyde, 2-amino-7-methyl-5-oxo-5H-1benzopyrano2,3-bpyridine-3-carbonitrile, 1-amino-anthraquinone, anthraquinone-2-carboxylic acid, 1,5-dihydroxyanthraquinone, anthrone, 9-anthryle trifluoromethylketone, 9-alkylanthracene derivatives, 9-carboxylanthracene derivatives, 1-carboxylanthracene derivatives and mixtures thereof to obtain a filtrate;
coating the filtrate on a lower layer of a substrate to form a cotated layer thereon; and
hard-baking the coated layer.
15. The method of claim 14, wherein the organic solvent is selected from the group consisting of ethyl-3-ethoxypropionate, methyl 3-methoxypropionate, cyclohexanone, and propyleneglycolmethylether acetate and is used in an amount ranging from about 200 to about 5,000 wt. % based on the total weight of the anti-reflective coating resin used.
16. The method of claim 14, wherein the hard-baking step is carried out at a temperature ranging from about 100 to about 300 C.
17. A semiconductor device prepared from the anti-reflective coating composition of claim 12.
18. A semiconductor device prepared from the anti-reflective coating composition of claim 13.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of treating a subject having glomerulonephritis, the method comprising administering to said subject at least one peptide that binds to an anti-double stranded-DNA antibody in the subject, wherein said peptide comprises a D-amino acid sequence of X1-Trp-X1-Tyr-X2, wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.
2. The method according to claim 1 wherein said peptide is 5 to about 30 D-amino acids in length.
3. The method according to claim 1 wherein said peptide is 5 to about 15 D-amino acids in length.
4. The method according to claim 1 wherein said peptide is 5 to about 10 D-amino acids in length.
5. The method according to claim 1 wherein said peptide is 5 D-amino acids in length.
6. The method according to claim 1 wherein said peptide is 5 to about 30 amino acids in length and comprises d-Asp-Trp-Glu-Tyr-Ser.
7. The method according to claim 6 wherein said peptide is 5 to about 15 amino acids in length.
8. The method according to claim 6 wherein said peptide is 5 to about 10 amino acids in length.
9. The method according to claim 6 wherein said peptide consists of d-Asp-Trp-Glu-Tyr-Ser.